Gil Aharon
Gil Aharon's purchase track record
How the stock did after each of Gil Aharon's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/23/2025 | NRXS | $1.01M | +102.6% | +101.2% | +6.6% |
| 3/19/2024 | DCTH | $100K | +78.5% | +119.2% | +8.8% |
| 4/18/2022 | DCTH | $13K | -37.1% | -53.8% | -16.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Veracyte stock moves; DCTH shows no related news. Recent news coverage focuses on Veracyte (VCYT) rather than Delcath Systems (DCTH). There are no specific reports or announcements regarding DCTH in the provided data. The stock currently trades with a high trailing P/E ratio, while analyst targets remain above the current price level.
Transaction History
| NRXS | ▲ Buy | Grant | 43,930 | $276K | 8/13/2026 | View on chart |
| NRXS | ▲ Buy | Grant | 40,068 | — | 7/29/2026 | View on chart |
| NRXS | ▲ Buy | Grant | 2,226 | — | 7/29/2026 | View on chart |
| NRXS | ▲ Buy | Grant | 12,304 | — | 4/28/2026 | View on chart |
| NRXS | ▲ Buy | Grant | 221,917 | — | 4/28/2026 | View on chart |
| NRXS | ▲ Buy | Grant | 21,598 | $100K | 1/22/2026 | View on chart |
| NRXS | ▲ Buy | Open Market | 286,138 | $1.0M | 12/23/2025 | View on chart |
| DCTH | ▼ Sell | Other | 400,000 | $4.0M | 5/5/2025 | View on chart |
| DCTH | ▼ Sell | Other | 250,000 | $2.5M | 12/24/2024 | View on chart |
| DCTH | ▼ Sell | Other | 619,946 | $3843.3M | 4/18/2024 | View on chart |
| DCTH | ▼ Sell | Other | 991,615 | $0 | 4/18/2024 | View on chart |
| DCTH | ▲ Buy | Open Market | 26,882 | $100K | 3/19/2024 | View on chart |
| DCTH | ▲ Buy | Open Market | 2,000 | $13K | 4/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth
NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.
NeurAxis Names Craig Blanchard CCO to Drive Commercial Growth. NeurAxis has appointed Craig Blanchard as chief commercial officer to lead the next phase of commercial growth. The move signals the company’s focus on expanding market reach and accelerating product commercialization. Blanchard’s experience is expected to help the firm move from development to broader market adoption.